Quote:

---

Coya yesterday reported their low dose Il-2 phase 2 Alzheimer's results. Seems mixed results with lower dosage of treatment every four weeks providing a slowing in cognitive decline. Meanwhile, higher dosage of treatment every two weeks appeared no better than placebo.

---

No surprise there. Lower amounts of IL-2 would increase T-regulatory cells decreasing inflammation a bit. Higher levels of IL-2 increase inflammatory cytokines and cell killing macrophages which would negatively affect Alzheimer's.